Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study
| Autor: | Constantin Potagas, George N. Papadimitriou, Demetrios Vassilopoulos, Iannis M. Zervas, Panagiotis Mitropoulos, Constantin Sfagos, Charalampos Mitsonis, Nikolaos Dimopoulos |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent One year follow up Treatment as usual Citalopram Life Change Events Multiple Sclerosis Relapsing-Remitting Internal medicine mental disorders Secondary Prevention medicine Humans Escitalopram Pharmacology (medical) Psychiatry Prospective cohort study Biological Psychiatry Pharmacology Multiple sclerosis Life events medicine.disease Psychiatry and Mental health Treatment Outcome Increased risk Neurology Female Neurology (clinical) Open label Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | European Neuropsychopharmacology. 20:123-131 |
| ISSN: | 0924-977X |
| Popis: | A growing body of evidence supports the association between Stressful Life Events (SLEs) and increased risk for relapse in Multiple Sclerosis (MS). In this open-label, randomized, controlled, one-year prospective study we investigated the effects of escitalopram on stress-related relapses in 48 women with relapsing-remitting MS. Patients were randomly assigned either to receive escitalopram 10mg/day (e-group, N=24) or to continue with treatment as usual, as a control group (c-group, N=24). SLEs were documented weekly in self-report diaries and were classified afterwards as short- or long-term depending on their psychological impact as this was subjectively felt by the patient. The cumulative risk for relapse was 2.9 times higher for controls than for escitalopram-treated patients (95% CI=1.7-5.1, p0.001) and it was influenced only by long-term SLEs. In the e-group only 3 or more long-term SLEs were associated with a significant increase of the risk of a relapse during the following 4 weeks, and this risk was 4 times lower compared to the c-group. Our study shows preliminary evidence that escitalopram may constitute an effective and well-tolerated treatment option for the prevention of stress-related relapses in women with MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect